Lipid metabolism within the duodenum increases long-chain fatty acyl-CoA levels ([@B1]) and cholecystokinin (CCK) release that leads to the activation of duodenal CCK-A receptors and an inhibition of glucose production ([@B2]). The necessary step(s) that mediate the ability of duodenal long-chain fatty acyl-CoA to stimulate CCK release to regulate glucose production, however, remains unknown.

Novel protein kinase C (PKC) isoforms such as δ and θ are activated by lipids in the brain ([@B3],[@B4]) and δ, θ, and ε in the liver ([@B5]) to regulate glucose production. It is noteworthy that PKC-δ is also expressed in the duodenum ([@B6],[@B7]) and that activation of duodenal mucosal PKC-δ inhibits glucose production ([@B6]). Although duodenal PKC-δ activation ([@B6]) or CCK action ([@B2]) is necessary for lipid sensing and sufficient to trigger a gut--brain--liver axis to lower glucose production, the interfunctional relationship between PKC-δ and CCK has yet to be established.

Two sets of studies report a potential mechanistic link between PKC and CCK. First, oleate activates PKC and stimulates CCK release in a CCK-secreting cell line ([@B8],[@B9]). Conversely, CCK binds to the G-protein--coupled CCK-A receptor and stimulates the phospholipase C signaling pathway to activate PKC-δ and PKC-ε in pancreatic acinar cells ([@B10]--[@B12]). Together, these findings suggest that activation of duodenal PKC-δ may lie upstream (and/or downstream) of CCK signaling to trigger a neuronal network to regulate glucose production ([Fig. 1*A*](#F1){ref-type="fig"} and [Supplementary Fig. 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0852/-/DC1)).

![*A*: Schematic representation of the working hypothesis. OAG with or without MK-329 or CR-1409 infused through a duodenal catheter. *B*: Experimental procedure and clamp protocol. Duodenal catheter or venous and arterial catheters were implanted on day 1. On the evening before the pancreatic (basal insulin) clamp studies, all rats received a fixed portion of calories (∼58 kcal) to ensure a comparable postabsorptive state at the start of the clamp experiments. *C*: Immunohistochemical stain of PKC-δ (*left*), CCK (*center*), and colocalization of PKC-δ and CCK (*right*) in the rat duodenum. PKC-δ stain is green, CCK stain is red, PKC-δ + CCK stain is orange, and nuclear stain is blue. Intraduodenal OAG infusion increased the glucose infusion rate (*D*) and decreased glucose production (*E* and *F*). Coinfusion of OAG with MK-329 or CR-1409 abolished the effect of OAG on the glucose infusion rate (*D*) and glucose production (*E* and *F*). *G*: Glucose uptake was comparable in all groups. \*\**P* \< 0.01 vs. all other groups. Saline (*n* = 6), OAG (*n* = 7), saline + MK-329 (*n* = 5), OAG + MK-329 (*n* = 5), saline + CR-1409 (*n* = 5), and OAG + CR-1409 (*n* = 5) are shown. Values are shown as mean + SEM. IV, intravenous; NMDA, N-methyl-[d]{.smallcaps}-aspartate; NTS, nucleus of the solitary tract; SAL, saline; SRIF, somatostatin. (A high-quality digital representation of this figure is available in the online issue.)](3148fig1){#F1}

In this study, we attempt to clarify whether duodenal PKC-δ and CCK signaling converges (or diverges) to regulate glucose production. We first examined whether PKC-δ and CCK expression is colocalized in the duodenal mucosa. We then performed pharmacological and molecular gain- and loss-of-function experiments targeting PKC-δ and CCK-A receptor signaling within the intestine to determine whether duodenal PKC-δ activation lies upstream and/or downstream of CCK signaling to regulate glucose production.

RESEARCH DESIGN AND METHODS {#s5}
===========================

Animal preparation. {#s6}
-------------------

The protocols were approved by the Institutional Animal Care Committee of the University Health Network. Male SD rats (250--300 g) were housed in individual cages and maintained on a standard light-dark cycle. The rats had access to chow and water ad libitum and were given 7 days to acclimatize before the designated surgeries were performed.

Duodenal and intravenous cannulations. {#s7}
--------------------------------------

Duodenal cannulation was performed where a catheter was inserted into the proximal duodenum (∼1.5--2 cm downstream of the pyloric sphincter) ([@B1],[@B2]). Intravenous catheters were placed into the internal jugular vein and carotid artery for infusion and blood sampling, respectively ([@B1],[@B2]). Rats were monitored for daily food intake and body weight for 3 to 4 days after surgery and only underwent clamp studies when food intake and body weight were recovered back to at least 90% of basal values. A subgroup of rats with duodenal and intravenous catheters implanted were placed on a lard-oil enriched high-fat diet for 3 days (Purina Mills \[TestDiet\]; No. 0009389) that induces duodenal lipid/CCK resistance ([@B1],[@B2]).

Intraduodenal infusion and the pancreatic (basal insulin)-euglycemic clamp. {#s8}
---------------------------------------------------------------------------

The clamp was performed as described ([@B1],[@B2]) ([Fig. 1*B*](#F1){ref-type="fig"}). The night before, rats were restricted to ∼58 kcal of food to ensure the same nutritional postabsorptive status. At *t* = 0 min, a primed continuous infusion of \[3-^3^H\]glucose (bolus 40 μCi; 0.4 μCi/min) was given, and this rate was maintained throughout to assess changes in steady-state glucose kinetics based on tracer-dilution methodology. The clamp was started at *t* = 90 min whereby a continuous infusion of insulin at 1.2 mU/kg/min and somatostatin at 3 μg/kg/min were initiated. Somatostatin suppressed the plasma C-peptide level by \>80% (basal: 0.63 ± 0.05 nmol/L vs. clamp: 0.12 ± 0.03; *n* = 14/group). A 25% glucose solution was infused at a variable rate to maintain euglycemia. The glucose infusion was adjusted every 10 min from *t* = 120--200 min. Intraduodenal infusions were initiated at *t* = 150 min and maintained until *t* = 200 min at 0.01 mL/min. Blood samples were taken at *t* = 90, 180, and 200 min to determine plasma insulin and C-peptide levels. Of note, during the clamps, plasma insulin levels (saline: 0.7 ± 0.2; 1-oleoyl-2-acetyl-sn-glycerol \[OAG\]: 0.7 ± 0.1; saline ± MK-329: 0.7 ± 0.1; OAG ± MK-329: 0.6 ± 0.1) were comparable among individual groups.

The following reagents were administered intraduodenally: *1*) saline; *2*) OAG--PKC activator (Calbiochem; 250 μmol/L); *3*) CCK-8 (sulfated)--CCK receptor agonist (Sigma-Aldrich; 35 pmol/kg/min); *4*) MK-329--CCK-A receptor antagonist (Tocris Bioscience; 3.2 μg/kg/min); *5*) CR-1409--CCK-A receptor antagonist (Sigma-Aldrich; 29 μg/kg/min), and *6*) rottlerin--PKC-δ specific inhibitor (Calbiochem; 60 μmol/L).

Virus injection and surgery. {#s9}
----------------------------

Adenovirus (Ad) application into the duodenum was performed as described ([@B6]). Ad expressing LacZ or the dominant negative form (DN) of PKC-δ (pfu/mL = 4 × 10^8^; 0.2 mL; gift from Dr. J. Soh, Biomedical Research Centre for Signal Transduction Network, Incheon, Korea) was injected into the duodenal lumen. A duodenal catheter was subsequently inserted through the injection site, followed by vascular cannulation using the same procedures described earlier. Animals were allowed to recover for 3 days before the clamp procedures. We have validated previously that duodenal injection of Ad expressing LacZ selectively infected intestinal cells, but not hepatocytes, to a detectable level ([@B3]).

Immunofluorescence. {#s10}
-------------------

Duodenal tissues were collected for immunofluorescence staining after animals were killed. After sectioning, the sections were postfixed with 4% PFA and Tween-20 (0.05%) and were blocked with 10% goat serum in phosphate-buffered saline for 1 h. To check for PKC-δ and CCK immunoreactivity, the sections were incubated with mouse anti--PKC-δ antibody (1:100) and rabbit anti--CCK-8 antibody (1:200) overnight at 4°C, respectively. The sections were incubated with goat anti-mouse antibody (1:500) and anti-rabbit antibody (1:200) for 1 h at room temperature. Immunolabeling was detected with the aid of a fluorescence microscope.

Biochemical analysis. {#s11}
---------------------

Plasma glucose concentrations were measured using the glucose oxidase method (Glucose analyzer GM9; Analox Instruments). Plasma insulin and C-peptide concentrations were measured using RIA (Linco Research).

Calculations. {#s12}
-------------

Statistical analysis was performed using ANOVA followed by Tukey *t* test post hoc analysis. Significance was accepted at *P* \< 0.05. Data are presented as means + SEM. The time period 60--90 min was averaged for the basal condition, and the time period 180--200 min was averaged for the clamp condition.

RESULTS {#s13}
=======

Oleate activates PKC and stimulates CCK release within the same CCK-secreting cells ([@B8],[@B9]). If duodenal CCK signaling is necessary for PKC-δ activation to regulate glucose, PKC-δ should be colocalized with CCK in the duodenal mucosa. Immunostaining of CCK indicated that CCK was expressed along the duodenal mucosa ([Fig. 1*C*](#F1){ref-type="fig"}) where the I cells that release CCK ([@B13]) are found. PKC-δ was expressed around the same area that contained CCK ([Fig. 1*C*](#F1){ref-type="fig"}), and PKC-δ appeared to colocalize with CCK ([Fig. 1*C*](#F1){ref-type="fig"}), suggesting a mechanistic link between PKC-δ and CCK.

To evaluate whether duodenal CCK signaling is required for duodenal mucosal PKC-δ activation to regulate glucose kinetics, we activated duodenal mucosal PKC-δ and inhibited the duodenal CCK-A receptor via intraduodenal coinfusion of OAG with either MK-329 or CR-1409 in normal rats during the clamps ([Fig. 1*A* and *B*](#F1){ref-type="fig"}). When intraduodenal OAG was infused at a dose that activated duodenal mucosal PKC-δ activity ([@B6]), the glucose infusion rate required to maintain euglycemia was increased ([Fig. 1*D*](#F1){ref-type="fig"}) as a result of an inhibition of glucose production ([Fig. 1*E* and *F*](#F1){ref-type="fig"}). Coinfusion of either intraduodenal MK-329 or CR-1409 with OAG fully negated the ability of OAG to increase glucose infusion rate ([Fig. 1*D*](#F1){ref-type="fig"}) and lower glucose production ([Fig. 1*E* and *F*](#F1){ref-type="fig"}), whereas duodenal MK-329 or CR-1409 alone had no effects ([Fig. 1*D*--*F*](#F1){ref-type="fig"}). Glucose uptake was comparable in all groups ([Fig. 1*G*](#F1){ref-type="fig"}). These data indicate that activation of the duodenal CCK-A receptor is required for PKC-δ activation to lower glucose production, suggesting that PKC-δ activation lies upstream of CCK signaling.

It is equally possible that duodenal PKC-δ signaling lies downstream of CCK ([Supplementary Fig. 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0852/-/DC1)). We first tested the metabolic effects of duodenal CCK signaling ([Supplementary Fig. 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0852/-/DC1)), and consistent with a previous report ([@B2]), intraduodenal CCK-8 infusion increased the glucose infusion rate ([Fig. 2*A*](#F2){ref-type="fig"}) and lowered glucose production ([Fig. 2*B* and *C*](#F2){ref-type="fig"}) but did not alter glucose uptake ([Fig. 2*D*](#F2){ref-type="fig"}). The intraduodenal PKC-δ inhibitor rottlerin infused at a dose that blocked the metabolic effects of OAG ([@B6]) failed to negate the ability of intraduodenal CCK-8 to regulate glucose kinetics ([Fig. 2*A*--*D*](#F2){ref-type="fig"}).

![*A*: Intraduodenal CCK-8 infusion increased the glucose infusion rate, and the increase in glucose infusion rate remained when CCK-8 was coadministered with rottlerin (ROT). *B* and *C*: Glucose production during the clamps. *D*: Glucose uptake during the clamps. Saline (SAL; *n* = 7), CCK-8 (*n* = 6), rottlerin alone (*n* = 5), and CCK-8 + rottlerin (*n* = 5) are shown. \*\**P* \< 0.01 vs. saline. *E*: Intraduodenal infusion of CCK-8 increased the glucose infusion rate in both Ad LacZ-- and Ad DN PKC-δ--injected rats. *F* and *G*: Glucose production during the clamps. *H*: Glucose uptake during the clamps. Saline + Ad LacZ (*n* = 5), CCK-8 + Ad LacZ (*n* = 5), saline + Ad DN PKC-δ (*n* = 5), and CCK-8 + Ad DN PKC-δ (*n* = 5) are shown. \*\*\**P* \< 0.001, \**P* \< 0.05 vs. saline LacZ. Values are shown as mean + SEM.](3148fig2){#F2}

To alternatively exclude the downstream signaling possibility of duodenal PKC-δ to CCK, duodenal mucosal PKC-δ activity was knocked down with a molecular approach ([@B6]) ([Supplementary Fig. 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0852/-/DC1)). We injected the Ad expressing LacZ (control) or the DN of PKC-δ directly into the lumen of the duodenum. Duodenal mucosal PKC-δ activity was knocked down by ∼60% with intestinal Ad DN PKC-δ, and such inhibition of PKC-δ negated the ability of duodenal OAG to regulate glucose production ([@B6]). Intraduodenal CCK-8 was equally potent to increase the glucose infusion rate ([Fig. 2*E*](#F2){ref-type="fig"}) and lower glucose production ([Fig. 2*F* and*G*](#F2){ref-type="fig"}) in duodenal Ad LacZ--injected rats as compared with normal rats ([Fig. 2*A--C*](#F2){ref-type="fig"}). The metabolic effects induced by intraduodenal CCK-8 preserved in rats injected with duodenal Ad DN PKC-δ ([Fig. 2*E*--*G*](#F2){ref-type="fig"}). Glucose uptake was comparable in all groups ([Fig. 2*H*](#F2){ref-type="fig"}). These data together indicate that duodenal PKC-δ signaling is not required for (or not downstream of) CCK to regulate glucose production.

Given that selective activation of duodenal mucosal PKC-δ enhances CCK signaling to regulate glucose production in normal rats, we tested whether activation of duodenal PKC-δ is sufficient to enhance CCK signaling to overcome CCK resistance in response to high-fat feeding ([@B2]). Intraduodenal OAG increased the glucose infusion rate ([Fig. 3*A*](#F3){ref-type="fig"}) and lowered glucose production ([Fig. 3*B* and *C*](#F3){ref-type="fig"}) independent of changes in glucose uptake ([Fig. 3*D*](#F3){ref-type="fig"}) in normal rats. In contrast, intraduodenal OAG failed to alter glucose kinetics ([Fig. 3*A*--*C*](#F3){ref-type="fig"}) in rats fed with a high-fat diet. Thus, direct activation of duodenal PKC-δ fails to overcome CCK resistance in high fat-fed rats.

![During the pancreatic clamps, rats that were placed on a high-fat diet (HFD) for 3 days failed to respond to intraduodenal OAG infusion to increase the glucose infusion rate (*A*) and lower glucose production (*B* and *C*) compared with rats fed regular chow. *D*: Glucose uptake was comparable in all groups. \*\**P* \< 0.01 vs. all other groups. Regular chow (RC) + saline (SAL; *n* = 7), RC + OAG (*n* = 6), HFD + saline (*n* = 6), and HFD + OAG (*n* = 5) are shown. Values are shown as mean + SEM.](3148fig3){#F3}

DISCUSSION {#s14}
==========

Lipid metabolism within the duodenum triggers a neuronal network to lower glucose production in normal but not in high fat-fed rats ([@B1]). Given that diabetes and obesity are characterized by an excessive rate of glucose production ([@B14],[@B15]), studies aimed to dissect the underlying mechanisms of duodenal lipid sensing could reveal novel therapeutic molecules that lower glucose production in diabetes and obesity ([@B16]).

We here demonstrate that activation of the duodenal CCK-A receptor is necessary to mediate the metabolic effects of duodenal mucosal PKC-δ activation, thereby revealing a duodenal PKC-δ and CCK signaling axis that lowers glucose production in the presence of circulating basal insulin levels. Because activation of duodenal mucosal PKC-δ ([@B6]) or CCK-A receptors ([@B2]) is sufficient and necessary for lipid sensing to trigger a gut--brain--liver axis to lower glucose production in normal rats through the hepatic vagus, our data collectively indicate that metabolism of lipids within the duodenum activates mucosal PKC-δ and stimulates the release of CCK from the mucosal I cells, leading to the activation of CCK-A receptors (i.e., lipids→PKC-δ→CCK→CCK-A receptors) and lowering of glucose production. The mechanistic link(s) of the ability of PKC-δ to stimulate CCK release remains unknown. However, the potential involvement of the soluble NSF attachment protein receptor proteins (i.e., Munc18--1 and vesicle-associated membrane protein-2) warrants future investigation since PKC-δ enhances insulin secretion in association with increased phosphorylation of Munc18--1 in pancreatic β-cells ([@B17]) and vesicle-associated membrane protein-2 mediates CCK secretion in secreting tumor cell-1 cell lines ([@B18]).

Although the physiological relevance of the ability of the duodenal PKC-δ→CCK signaling axis to regulate glucose is supported by the fact that direct inhibition of either duodenal PKC-δ ([@B6]) or CCK-A receptors ([@B2]) disrupts glucose homeostasis during refeeding, the nutritional value of this newly described signaling axis remains to be explored. Experiments aimed to assess whether different types of long-chain fatty acid such as oleate or palmitate (via intraduodenal infusion or oral ingestion) trigger the PKC-δ→CCK signaling axis and regulate glucose production would begin to address the nutritional, physiological, and beneficial impact of this signaling pathway.

Rats acquired duodenal CCK resistance in response to high-fat feeding ([@B2]). Although the site(s) of the defect is unclear, evidence suggests that it lies within the signaling cascade of the duodenal CCK-A receptor since direct administration of the receptor agonist CCK-8 into the duodenum fails to lower glucose production in high fat-fed rats ([@B2]). Consistent with the fact that duodenal PKC-δ activation is upstream of CCK signaling and that diet-induced CCK resistance is postulated to lie within the downstream signaling cascade of CCK-A receptors, direct activation of duodenal mucosal PKC-δ still fails to overcome intestinal CCK resistance to lower glucose production. These findings strengthen the argument that duodenal lipid resistance is not a result of the inability of lipid to trigger signaling events (i.e., PKC-δ activation) to stimulate the local release of CCK from the mucosa, but rather, the downstream signaling cascade of CCK/CCK-A receptor.

Of note, although activation of duodenal PKC-δ is not required for CCK (i.e., CCK→CCK-A receptors→PKC-δ) to regulate glucose production, our present data do not rule out the possibility that the CCK-A receptor may activate other isoforms of PKC via phospholipase C to regulate glucose production, which warrants future investigation. In summary, the current set of data unveils a novel duodenal PKC-δ and CCK signaling axis that regulates glucose production in vivo.

This article contains Supplementary Data online at <http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0852/-/DC1>.
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